CAJ | 학술논문

通过分析美国近期发生的“Lilly vs Teva”生物医药专利重复授权纠纷案，深入研究美国专利重复授权的审查标准，在此基础上讨论我国目前重复授权的审查标准，指出存在的问题及可能带来的一些不利影响。最后结合美国重复授权审查标准，对我国重复授权审查标准的完善提出建议。
통과분석미국근기발생적“Lilly vs Teva”생물의약전리중복수권규분안，심입연구미국전리중복수권적심사표준，재차기출상토론아국목전중복수권적심사표준，지출존재적문제급가능대래적일사불리영향。최후결합미국중복수권심사표준，대아국중복수권심사표준적완선제출건의。
The examination standard for double patenting in the U.S. was deeply studied by analyzing the bio-pharmaceutical patent disputes concerning double patenting between Eli Lilly and Teva. On this basis, the examination standard of double patenting in China was discussed and the problems and possible adverse impact were also pointed out. And ifnally, several pieces of reasonable suggestions were proposed so as to complete Chinese examination standard of double patenting based on that in the U.S..